返回 
加入收藏
西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床疗效及安全性。方法：80例2型糖尿病合并代谢综合征的患者按照单纯随机抽样法分为观察组和对照组，各40例。两组患者均给予同样的饮食和运动方案，在此基础上，对照组患者口服二甲双胍，每次0.5 g，tid；观察组患者在对照组治疗基础上加服西格列汀，每次100 mg，qd。两组疗程均为12周。检测两组患者的腰围（WC）、体质量指数（BMI）、血糖、血脂、空腹胰岛素（FINS）、脂联素等指标水平，计算稳态模型胰岛素抵抗指数（HOMA-IR）和总体胰岛素敏感指数（WBISI），并观察不良反应发生情况。结果：治疗前，两组患者的WC、BMI、收缩压、舒张压、三酰甘油、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、空腹血糖、餐后2 h血糖、FINS、HOMA-IR、WBISI和脂联素水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者的上述各指标均较治疗前明显改善，且观察组改善程度明显优于对照组，差异均有统计学意义（P＜0.05）。对照组和观察组分别有2、3例患者因发生不良反应而退出研究。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床疗效显著，其机制可能与减轻胰岛素抵抗、增强胰岛素敏感性、减轻患者体质量及升高血清脂联素水平有关。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of sitagliptin combined with metformin in the treatment of type 2 diabetes complicating with metabolic syndrome. METHODS： Totally 80 patients with type 2 diabetes complicating with metabolic syndrome were divided into the observation group and control group with 40 cases in each group according to simple random sampling method. Both groups were given same diet and exercise plan； control group was additionally given metformin orally， 0.5 g each time， tid； observation group was additionally given sitagliptin， 100 mg each time， qd， on the basis of control group. Treatment course of 2 groups lasted for 12 weeks. The waist circumference （WC）， body mass index （BMI）， blood glucose， blood lipid， fasting insulin （FINS） and serum adiponectin were detected in 2 groups， and steady-state model insulin resistance index （HOMA-IR） and whole body insulin sensitivity index （WBISI） were calculated. The occurrence of ADR was observed. RESULTS： Before treatment， there were no statistically significant differences between 2 groups in WC， BMI， systolic blood pressure， diastolic blood pressure， triglycerides， cholesterol， high-density lipoprotein cholester， low-density lipoprotein cholesterol，fasting plasma glucose， 2 h postprandial blood glucose， FINS， HOMA-IR， WBISI and serum adiponectin （P＞0.05）. After treatment， the above indexes of 2 groups were obviously improved， and the improvement of observation group was significantly better than that of control group， with statistical significance （P＜0.05）. 2 cases and 3 cases were withdraw from the study in control group and observation group because of ADR， respectively.There was no statistically significant difference in the incidence of ADR between 2 groups （P＞0.05）. ?CONCLUSIONS： Sitagliptin combined with metformin shows significant clinical efficacy in the treatment of type 2 diabetes complicating with metabolic syndrome. Its mechanism may be related to reducing insulin resistance， enhancing insulin sensitivity， decreasing patients’ body weight and up-regulating serum adiponectin level. |
| 期刊： | 2016年第27卷第17期 |
| 作者： | 张坤，任巧华，吴韬，杜俊文 |
| AUTHORS： | ZHANG Kun，REN Qiaohua，WU Tao，DU Junwen |
| 关键字： | 2型糖尿病；代谢综合征；西格列汀；二甲双胍；血清脂联素；胰岛素抵抗 |
| KEYWORDS： | Type 2 diabetes； Metabolic syndrome； Sitagliptin； Metformin； Serum adiponectin； Insulin resistance |
| 阅读数： | 249 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
